ERBB2 and breast carcinoma: In HER2(−) breast cancer patients, there was no significant correlation between Ki67 and FT3 (r = −0.06, P = 0.67), FT4 (r = −0.15, P = 0.26), or TSH (r = −0.09, P = 0.49).